An observational study in Potentially Malignant Lesions, Oral Lichen Planus and Leukoplakia, Oral, sponsored by Fayoum University. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Fayoum University · Observational
Among 35 studies in Lichen Planus, Oral with a site in Egypt — 5 open to participants now, 7 under way, 2 of them phase 3. Lichen Planus, Oral · Egypt.
Among the 35 studies in Lichen Planus, Oral with a site in Egypt, this one is the 10th largest by enrollment of the 12 observational ones that give a count, is one of 3 that started in 2022, is one of 12 observational ones, and was the 15th registered.
142 studies on the registry are indexed under Lichen Planus, Oral; 27 are open to participants now.
Browse Lichen Planus, Oral studies →5 of the 35 studies in Lichen Planus, Oral with a site in Egypt are open now. Recruiting first, the newest first:
British University In Egypt · Sites in Egypt
Ages 18+ · Healthy volunteers
Cairo University · Sites in Egypt
October 6 University · Sites in Egypt
Ages 20–75
British University In Egypt · Sites in Egypt
Alexandria University · Sites in Egypt
Ages 18–65
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 14 Lichen Planus, Oral studies recruiting now, 10 (71%) set no upper age limit and 2 (14%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 3 · Phase 4 8
First in 2013; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 75 across 38 observational studies indexed under Lichen Planus, Oral.
Median enrollment 39 across the 23 interventional studies, 70 across the 12 observational. Of the 24 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 35 has an industry lead sponsor. The 10 most frequent:
Fayoum University is the lead sponsor of 149 studies on the registry; 45 are open to participants now.
Fayoum University has 3 studies filed under Lichen Planus, Oral — fewer than ten, so there is no comparison to draw.
3 of the studies in Lichen Planus, Oral with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07915570British University In EgyptSalivary IL-8 and Serum IL-6 as Biomarkers for Oral Potentially Malignant Disorders in Smokers and Never-Smokers | 2026-12-30 |
| NCT07846891Ain Shams UniversityLow Level Laser Therapy With Injectable Platelet Rich Fibrin in Management of Oral Lichen Planus | 2027-04-20 |
| NCT07910175Alexandria UniversityCurcumin-mediated Photodynamic Therapy Versus Photobiomodulation in the Treatment of Oral Erosive Lichen Planus | 2027-05-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 35 studies in Lichen Planus, Oral with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate salivary expression of lncRNA DQ786243 as a potential marker for diagnosis of oral potentially malignant lesions compared to normal controls and its effect on salivary expression of miRNA146a.
Egyptian Population
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group I: patients suffering from oral lichen planus Group II: patients suffering from leukoplakia Group III: healthy subjects who are systemically free, non-smokers, and not suffering from any oral mucosal lesions.
Exclusion Criteria:
Diagnostic Test: Real-time Polymerase Chain Reaction technique
Diagnostic Test: Real-time Polymerase Chain Reaction technique
Diagnostic Test: Real-time Polymerase Chain Reaction technique
Real-time Polymerase Chain Reaction technique
salivary expression of lncDQ786243 in OLP, Leukoplakia, control
Time frame: 2 months
salivary expression of miRNA146a in OLP, Leukoplakia, control
Time frame: 2 months
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Ran from Nov 2022 to primary completion in Dec 2022, 1 month.
Of 15 observational studies under Lichen Planus, Oral, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.